Related Articles
Efficacy of long‑term treatment with tenofovir in Chinese nucleos(t)ide‑naïve chronic hepatitis B patients regardless of baseline viral load
Efficacy and safety of tenofovir alafenamide fumarate in nucleoside analogue treatment-naïve patients with chronic hepatitis B
Serum IL‑21 levels predict HBeAg decline during rescue therapy in patients with partial response to nucleos(t)ide analogues
Predictors of therapeutic response to peginterferon α‑2a and nucleos(t)ide analog combination therapy for HBeAg‑negative chronic hepatitis B: 1‑year follow‑up after treatment
Serum HBsAg and HBeAg levels are associated with liver pathological stages in the immune clearance phase of hepatitis B virus chronic infection